Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
July 16, 2025
Biotechnology
-
-
Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions
July 16, 2025
-
Citius Oncology Announces Pricing of $9.0 Million Public Offering
July 16, 2025
-
Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement
July 16, 2025
-
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
July 15, 2025
-
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
July 15, 2025
-
ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction
July 14, 2025
-
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
July 11, 2025
-
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
July 11, 2025
-
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
July 10, 2025
-
Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
July 7, 2025
-
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
July 7, 2025
-
Hemostemix’s VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments!
July 2, 2025
-
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
June 2, 2025
-
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
May 30, 2025
-
Sequire Spotlight Presents: Biolargo (BLGO) – 45% Revenue Growth & PFAS Tech Driving Market Impact
May 22, 2025